PRKDC and B-cell chronic lymphocytic leukemia: Remarkably, CC-115, a dual inhibitor targeting DNA-PK and the structurally related mammalian target of rapamycin kinase (TORK), was shown to induce caspase-dependent cell death in primary chronic lymphocytic leukemia (CLL) cells and to be clinically effective in CLL patients with an ATM mutation (75, 76).